Bisphosphonate actions: Physical chemistry revisited

Bone

Volumn 38, Issue 5, 2006, Pages 613-616

  Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

BINDING AFFINITY; BONE METASTASIS; BONE TURNOVER; CLINICAL RESEARCH; DRUG HALF LIFE; HUMAN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL CHEMISTRY; REVIEW;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS;

EID: 33646079633     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.01.141     Document Type: Review

References (30)

1. Fleisch H. Bisphosphonates: mechanisms of action and clinical applications. In: Peck W.A. (Ed). Bone and Mineral Research Annual 1 (1982), Excerpta Medica, Amsterdam 319-357
2. L. Rosenstein, Process of treating water. US patent No 2038316 1936.
3. Blomen L.J.M.J. History of the bisphosphonates: discovery and history of the non medical uses of bisphosphonates. In: Bijvoet O.L.M., Fleisch H.A., Canfield R.E., and Russell R.G.G. (Eds). Bisphosphonates on Bones (1995), Elsevier, Amsterdam 111-124
4. Shinoda H., Adamek G., Felix R., Fleisch H., Schenk R., and Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int. 35 (1983) 87-99
5. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 11 (2003) 196-214
6. Reszka A.A., and Rodan G.A. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev. Med. Chem. 4 (2004) 711-719
7. Geddes A.D., D'Souza S.M., Ebetino F.H., and Ibbotson K.J. Bisphosphonates: structure-activity relationships and therapeutic implications. In: Heersche J.N.M., and Kanis J.A. (Eds). Bone and Mineral Research vol. 8 (1994), Elsevier Science, Amsterdam 265-306
8. Benedict J.J. The physical chemistry of the diphosphonates-Its relationship to their structural activity. In: Donath A., and Courvoisier B. (Eds). Symposium CEMO IV. Nyon Switzerland (1982), Editions Medecine est Hygiene, Geneva 1-19
9. van Beek E., Hoekstra M., van de Ruit M., Lowik C., and Papapoulos S. Structural requirements for bisphosphonates actions in vitro. J. Bone Miner. Res. 12 (1994) 1875-1882
10. van Beek E.R., Lowik C.W.G.M., Ebetino F.H., and Papapoulos S.E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone 23 (1998) 437-442
11. van Beek, Lowik C., Que I., and Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J. Bone Miner. Res. 11 (1996) 1492-1497
12. Brown R.J., van Beek E., Watts D.J., Lowik C.W.G.M., and Papapoulos S.E. Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of the Dictyostelium discoideum. J. Bone Miner. Res. 13 (1998) 253-258
13. Rogers M.J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif. Tissue Int. 75 (2004) 451-461
14. Leu C.-T., Luegmayr E., Freedman L.P., Rodan G.A., and Reszka A.A. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38 (2006) 628-636
15. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2005) 10.1016/j.bone.2005.05.003 [Electronic publication]
16. Cremers S.C.L.M., Pillai G., and Papapoulos S.E. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis. Clin. Pharmacokinet. 44 (2005) 551-570
17. Christiansen C., Phipps R., Burgio D., Sun L., Russell D., Keck B., et al. Comparison of risedronate and alendronate pharmacokinetics at clinical doses. Osteoporosis. Int. 14 Suppl. 7 (2003) S38
18. Rosen C.J., Hochberg M., Bonnick S., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate compared to once-weekly risedronate in women with postmenopausal osteoporosis: a randomized, double-blind study. J. Bone Miner. Res. 20 (2005) 141-151
19. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88 (1991) 2095-2105
20. Kasting G.B., and Francis M.D. Retention of etidronate in human, dog and rat. J. Bone Miner. Res. 7 (1992) 513-522
21. Cremers S.C.L.M., Papapoulos S.E., Gelderblom H., Seynaeve C., den Hartigh J., Vermeij P., et al. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J. Bone Miner. Res. 20 (2005) 1543-1547
22. Khan S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Miner. Res. 12 (1997) 1700-1707
23. Papapoulos S., Brumsen C., Hamdy N., and Cremers S. Bisphosphonate release following cessation of long-term treatment of children with osteoporosis. Bone 36 Suppl. 2 (2005) S415
24. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346 (2002) 653-661
25. McClung M.R., Wasnich R.D., Hosking D.J., Christiansen C., Ravn P., Wu M., et al. Early postmenopausal intervention cohort study. Prevention of postmenopausal bone loss: six-year results from the early postmenopausal intervention cohort study. J. Clin. Endocrinol. Metab. 89 (2004) 4879-4885
26. Wasnich R.D., Bagger Y.Z., Hosking D.J., McClung M.R., Wu M., Mantz A.M., et al. Early postmenopausal intervention cohort study group. Changes in bone mineral density and turnover after alendronate or estrogen withdrawal. Menopause 11 (2004) 622-630
27. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Alendronate phase III osteoporosis treatment group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350 (2004) 1189-1199
28. Black D., Schwartz A., Ensrud K., Rybak-Feiglin A., Gupta J., Lombardi A., et al. A 5 year randomized trial of the long-term efficacy and safety of alendronate: the FIT long-term extension (FLEX). J. Bone Miner. Res. 19 Suppl. 2 (2004) S45
29. Landman J.O., Hamdy N.A.T., Pauwels E.K.J., and Papapoulos S.E. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J. Clin. Endocrinol. Metab. 80 (1995) 3465-3468
30. Watts N.B., Olszynski W.P., McKeever C.D., Grauer A., and Chines A. Treatment discontinuation effects on bone turnover and BMD with risedronate. Bone 34 Suppl. 1 (2004) S99